STOCK TITAN

Avalo Therapeutics (AVTX) CMO trades 1,450 shares in 10b5-1 exercise-and-sell

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Avalo Therapeutics Chief Medical Officer Doyle Mittie reported an exercise-and-sell transaction in company stock. On June 23, 2026, Mittie exercised options to acquire 1,450 shares of Common Stock at $8.04 per share and sold 1,450 shares at $18.00 per share in an open-market sale. Following these transactions, Mittie directly holds 51,776 Common shares and 116,871 stock options. The filing notes that these trades were made under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were pre-scheduled rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
Insider Doyle Mittie
Role Chief Medical Officer
Sold 1,450 shs ($26K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 1,450 $0.00 --
Exercise Common Stock 1,450 $8.04 $12K
Sale Common Stock 1,450 $18.00 $26K
Holdings After Transaction: Stock Option (Right to Buy) — 116,871 shares (Direct, null); Common Stock — 53,226 shares (Direct, null)
Footnotes (1)
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Shares sold 1,450 shares Common Stock sold on June 23, 2026 at $18.00
Sale price $18.00 per share Open-market sale of 1,450 Common Stock shares
Options exercised 1,450 shares Common Stock acquired via option exercise on June 23, 2026
Exercise price $8.04 per share Conversion price for exercised stock option
Shares held after 51,776 shares Direct Common Stock holdings following transactions
Options remaining 116,871 options Direct stock option holdings after the reported exercise
10b5-1 plan adoption date November 13, 2025 Date Doyle Mittie adopted the trading plan governing these trades
Option expiration January 28, 2035 Expiration date for the exercised stock option grant
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock option (right to buy) financial
"Stock Option (Right to Buy) with 1,450 underlying Common Stock shares..."
open-market sale financial
"transaction_action: open-market sale for 1,450 shares of Common Stock..."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security..."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Common Stock financial
"security_title: Common Stock involved in sale and option exercise..."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Doyle Mittie

(Last)(First)(Middle)
C/O AVALO THERAPEUTICS, INC.
1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)
WAYNE PENNSYLVANIA 19087

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/23/2026M(1)1,450A$8.0453,226D
Common Stock06/23/2026S(1)1,450D$1851,776D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$8.0406/23/2026M(1)1,450 (2)01/28/2035Common Stock1,450$0116,871D
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
2. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
/s/ Christopher Sullivan, Attorney-in-Fact06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Avalo Therapeutics (AVTX) report for Doyle Mittie?

Avalo Therapeutics reported that Chief Medical Officer Doyle Mittie exercised options for 1,450 shares and sold 1,450 Common Stock shares on June 23, 2026. The activity reflects an exercise-and-sell pattern rather than a pure open-market purchase or sale.

At what prices did Doyle Mittie exercise and sell Avalo Therapeutics (AVTX) shares?

Doyle Mittie exercised stock options to acquire 1,450 Avalo Therapeutics shares at $8.04 per share and sold 1,450 Common Stock shares at $18.00 per share. This spread shows the economic value realized from converting options into stock and selling in the market.

How many Avalo Therapeutics (AVTX) shares does Doyle Mittie hold after this Form 4?

After the reported transactions, Doyle Mittie directly holds 51,776 shares of Avalo Therapeutics Common Stock. The filing also shows 116,871 stock options remaining, indicating continued equity exposure through both direct ownership and unexercised options.

Were Doyle Mittie’s Avalo Therapeutics (AVTX) trades made under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Such plans pre-schedule trades, reducing the significance of timing as a signal of management’s short-term view.

What type of derivative security did Doyle Mittie exercise at Avalo Therapeutics (AVTX)?

The filing shows an exercise of a stock option (right to buy) for 1,450 underlying Common Stock shares at a $8.04 conversion price. The option expires on January 28, 2035, and remains part of a larger option position after this partial exercise.